Angiotensin II receptor blocker suppresses liver fibrosis and carcinogenesis in rat non-alcoholic steatohepatitis model

被引：0
|
作者：
Kuang, Xiaochen [1 ]
Naiki, Aya [1 ]
Komura, Masayuki [1 ]
Kato, Hiroyuki [1 ]
Takahashi, Satoru [1 ]
机构：
[1] Nagoya City Univ, Dept Exp Pathol Tumor Biol, Nagoya, Aichi, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2001
引用
收藏
页码：869 / 869
页数：1
相关论文
共 50 条
  • [1] Chemopreventive effects of angiotensin-II receptor blocker on rat non-alcoholic steatohepatitis and carcinogenesis
    Kuang, Xiaochen
    Naiki, Aya
    Komura, Masayuki
    Kato, Hiroyuki
    Takahashi, Satoru
    CANCER SCIENCE, 2024, 115 : 506 - 506
  • [2] Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
    Yoshiji H.
    Noguchi R.
    Ikenaka Y.
    Namisaki T.
    Kitade M.
    Kaji K.
    Shirai Y.
    Yoshii J.
    Yanase K.
    Yamazaki M.
    Tsujimoto T.
    Kawaratani H.
    Akahane T.
    Aihara Y.
    Fukui H.
    BMC Research Notes, 2 (1)
  • [3] Effect of Losartan on liver fibrosis development in a rat model of non-alcoholic steatohepatitis
    Ibanez, P
    Pizarro, M
    Solis, N
    Aguayo, G
    Duarte, I
    Accatino, L
    Arrese, MA
    GASTROENTEROLOGY, 2004, 126 (04) : A688 - A689
  • [4] PROFILING FIBROSIS REGRESSION IN A RAT MODEL OF NON-ALCOHOLIC STEATOHEPATITIS
    Schaub, Johanna
    Lee, Gail
    Jenkins, Katherine
    Chen, Tony
    Martin, Shamra
    Rao, Vikram
    Marlow, Megan
    Ho, Steve
    Decaris, Martin
    Chen, Chun
    Turner, Scott
    HEPATOLOGY, 2020, 72 : 212A - 212A
  • [5] Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis
    Sawada, Yasuhiko
    Kawaratani, Hideto
    Kubo, Takuya
    Fujinaga, Yukihisa
    Furukawa, Masanori
    Saikawa, Soichiro
    Sato, Shinya
    Seki, Kenichiro
    Takaya, Hiroaki
    Okura, Yasushi
    Kaji, Kosuke
    Shimozato, Naotaka
    Mashitani, Tsuyoshi
    Kitade, Mitsuteru
    Moriya, Kei
    Namisaki, Tadashi
    Akahane, Takemi
    Mitoro, Akira
    Yamao, Junichi
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2019, 49 (03) : 284 - 295
  • [6] Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis
    Shirai, Yusaku
    Yoshiji, Hitoshi
    Noguchi, Ryuichi
    Kaji, Kosuke
    Aihara, Yosuke
    Douhara, Akitoshi
    Moriya, Kei
    Namisaki, Tadashi
    Kawaratani, Hideto
    Fukui, Hiroshi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (04) : 723 - 730
  • [7] Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis
    Sugino, Haruko
    Kumagai, Naoki
    Watanabe, Sakiko
    Toda, Kyoko
    Takeuchi, Osamu
    Tsunematsu, Satoshi
    Morinaga, Shojiroh
    Tsuchimoto, Kanji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (12) : 1909 - 1916
  • [8] Angiotensin II type I receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis
    Hirose, Akira
    Ono, Masafumi
    Saibara, Toshiji
    Nozaki, Yasuko
    Masuda, Kosei
    Yoshioka, Akemi
    Takahashi, Masaya
    Akisawa, Naoaki
    Iwasaki, Shinji
    Oben, Jude A.
    Onishi, Saburo
    HEPATOLOGY, 2007, 45 (06) : 1375 - 1381
  • [9] Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
    Tacke, Frank
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (03) : 301 - 311
  • [10] The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis
    Mendez-Sanchez, Nahum
    Valencia-Rodriguez, Alejandro
    Coronel-Castillo, Carlos
    Vera-Barajas, Alfonso
    Contreras-Carmona, Jocelyn
    Ponciano-Rodriguez, Guadalupe
    Zamora-Valdes, Daniel
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (06)
12345